These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33965001)

  • 41. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The evidence for long-term benefits of restoration of CFTR function continues to grow.
    Boyle MP
    Am J Respir Crit Care Med; 2015 Oct; 192(7):774-6. PubMed ID: 26426780
    [No Abstract]   [Full Text] [Related]  

  • 43. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ivacaftor CFTR Potentiator Therapy is Efficient for Pancreatic Manifestations in Cystic Fibrosis.
    Kounis I; Lévy P; Rebours V
    Am J Gastroenterol; 2018 Jul; 113(7):1058-1059. PubMed ID: 29887601
    [No Abstract]   [Full Text] [Related]  

  • 45. [Causal therapy is available].
    Meißner T
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
    [No Abstract]   [Full Text] [Related]  

  • 46. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cystic fibrosis drug Vertex's latest triumph.
    Ledford H
    Nat Biotechnol; 2012 Mar; 30(3):201-2. PubMed ID: 22398597
    [No Abstract]   [Full Text] [Related]  

  • 51. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Excitement mounts for first disease-modifying cystic fibrosis drugs.
    Opar A
    Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
    [No Abstract]   [Full Text] [Related]  

  • 53. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
    Kaiser J
    Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
    [No Abstract]   [Full Text] [Related]  

  • 55. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
    McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
    Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftor.
    Smith H; Rayment JH
    Pediatr Pulmonol; 2020 Oct; 55(10):2493-2494. PubMed ID: 32678518
    [No Abstract]   [Full Text] [Related]  

  • 57. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CFTR protein repair therapy in cystic fibrosis.
    Quintana-Gallego E; Delgado-Pecellín I; Calero Acuña C
    Arch Bronconeumol; 2014 Apr; 50(4):146-50. PubMed ID: 24095197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radical new treatments for cystic fibrosis.
    Arch Dis Child; 2015 Aug; 100(8):727. PubMed ID: 26078470
    [No Abstract]   [Full Text] [Related]  

  • 60. Transformative therapies for rare CFTR missense alleles.
    Oliver KE; Han ST; Sorscher EJ; Cutting GR
    Curr Opin Pharmacol; 2017 Jun; 34():76-82. PubMed ID: 29032041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.